Precision oncology company Guardant Health Inc (Nasdaq: GH) announced on Wednesday that it has expanded its Guardant360 Liquid cancer testing capabilities with new epigenomic applications designed to improve treatment selection in advanced breast and lung cancers. Powered by its InfinityAI platform, the enhancements combine genomic and epigenomic insights to identify potential treatment options that conventional genomic biomarkers alone may miss.

The five advances include new epigenomic predictors to identify patients who may benefit from selective oestrogen receptor degraders (SERDs) in advanced breast cancer and immune checkpoint inhibitor (ICI) monotherapy in advanced non-small cell lung cancer (NSCLC). The test will also enable blood-based identification of PD-L1-negative patients without requiring tissue samples.

Additional capabilities use methylation analysis to identify 20-45% of ALK fusions and more than 250% additional MTAP deletions missed by genomic liquid testing alone. These insights could help identify patients eligible for targeted treatments and clinical trials, including emerging PRMT5 and MAT2A inhibitor approaches.

The expanded platform also combines tumour microenvironment characterisation with tumour mutational burden and microsatellite instability to assess potential immunotherapy response and inform treatment decisions between ICI monotherapy and chemoimmunotherapy.

Guardant said the developments extend the clinical applications of its oncology testing portfolio, providing a more comprehensive view of tumour biology to support personalised cancer treatment decisions.